Drugs & pharma · US
Drugs & pharma · US · 12 stories in 48h · Clear all filters
SectorsNovartis 1Novo Nordisk 1
-
Novo Nordisk expands Novocare program for Wegovy users
-
Nexentis orders molecules for testing in drug discovery program
- The Mirror Pharmacist 'cautions' Ozempic and Wegovy users if taking warfarin
-
Kodiak Sciences at UBS Global Biopharma Conference 2026: two-drug push
- Ynetnews Weight-loss drug Wegovy shows promising results in children as young as 6, major study finds
- Yahoo Finance Eli Lilly is trouncing Nvidia — and the weight-loss drug trade is beating AI again
-
Six-year-olds: Novo’s new frontier for weight-loss drugsWegovy helped almost 8 in 10 children as young as 6 lose more than 10% of their BMI…
-
CNBC
Novo says Wegovy injection lowers BMI and obesity rates in children in trialWegovy is already approved to treat obesity in children ages 12 and older, but there are currently no…
- Yahoo Finance Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
-
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setbackShares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US…
-
Exelixis at UBS conference: zanzalintinib sets up next growth phase
-
Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica
1 more story in other languages (Portuguese 1) ·